Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 7/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859083 | 0.91 | CCR1 (0.44) | KCNJ1KCNH2CCR1 | |
| SCHEMBL5511464 | 0.89 | CCR1 (0.42) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3849571 | 0.84 | PDE4A (0.41) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3851829 | 0.83 | KCNN4 (0.44) | CCR1OPRL1OPRM1OPRK1TSHR | |
| SCHEMBL3852317 | 0.82 | OPRM1 (0.48) | OPRL1OPRM1OPRK1OPRD1AR | |
| SCHEMBL3861370 | 0.82 | OPRM1 (0.48) | CCR1OPRL1OPRM1OPRK1TSHR | |
| SCHEMBL3854368 | 0.81 | AR (0.42) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| Ethane SCHEMBL27686525 | 0.80 | DRD2 (0.38) | KCNJ1KCNH2CHRM2ARCHRM1 | |
| SCHEMBL3850884 | 0.78 | AR (0.50) | CCR1OPRL1OPRM1AR | |
| SCHEMBL3850839 | 0.76 | CCR1 (0.42) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | claimed |
| CN-101076517-A | Novel substituted piperidines as modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2007-11-21 | — | — | CN | claimed |
| CN-101076517-B | Substituted piperidines as modulators of dopamine neurotransmission | NSAB AF NEUROSEARCH SWEDEN AB | 2010-12-15 | — | — | CN | disclosed |
| US-7579474-B2 | Substituted piperidines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) | 2009-08-25 | — | — | US | disclosed |
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-11-22 | — | — | US | disclosed |
| CN-101076517-A | Novel substituted piperidines as modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2007-11-21 | — | — | CN | disclosed |
| EP-1765779-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121092-A1 | NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270467-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, PRLHR, DRD3 | KCNJ1 432/4885KCNH2 346/4885CCR1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.